Controlled clinical (6) and field (3, 11, 21) trials with school-age children and adults have established the Salmonella typhi Ty2la vaccine as effective in preventing typhoid fever. The vaccine is made of attenuated bacteria that are delivered orally. Ty2la engenders levels of protection from typhoid fever that are similar to those of parenteral vaccines (3, 11) ; however, Ty2la does not cause significant adverse reactions (6, 11) . Such reactions are common and sometimes severe after the administration of parenteral typhoid vaccines (1, 8, 22) .
It is established that DNA coding for protective antigens of various pathogenic microorganisms can be inserted into and successfully expressed by Ty21a and that the expressed gene products are immunogenic for humans (2, 5, 7, 14, (17) (18) (19) (20) . These (9, 12, 13, 15, 18) , measuring S. typhi-specific lymphocyte response (13, 15, 16) , and data processing and interpretation (13, 16) were as described previously.
In some instances the levels of measured antibodies or lymphocyte replication were used to classify individuals as positive for or lacking in an S. typhi-specific immune response. Classification as positive for the S. typhi-specific antibody response was determined as follows. When paired samples were available, positive was defined as a fourfold or greater rise in titer (11) ; when one sample was available, positive was defined as a titer of >20 or a net optical density (11) single samples were available, positive was defined as >3,433 cpm. It has been established (16) that this screening value in this assay has a resolving power in the detection of prior exposure of adults to S. typhi antigen of 82% sensitivity and specificity. The vaccine was well tolerated; 80% of the participants accepted .70 ml of formula at at least one of the immunizations, and similar acceptance was found for the vaccine and placebo formulations (P > 0.48, Fisher exact test).
Children from both vaccinated and placebo groups presented with a variety of notable signs (Table 1) . Of these, only one, a skin lesion, associated significantly with vaccination. The skin lesions appeared between 12 and 25 h after the first and/or second dose but not after the third dose of vaccine. These lesions were papules with erythema (2 to 4 mm in diameter) and were few in number (generally <10 per vaccinee); they were found on the trunk, face, and arms and resolved spontaneously by day 6 or 7 after the first vaccine dose. One vaccinee, 14 months old, was found to be febrile 18 h after the first vaccination dose. The fever persisted through 72 h. Samples of stool and blood were obtained at 24 and 48 h, and antibiotic therapy was begun at 48 h. The blood and stool cultures did not yield S. typhi. This child was not included in the rest of the protocol. The stool cultures from all volunteers at all sampled intervals were negative for S. typhi.
The criteria for inclusion in immunologic screening were completion of the immunization regimen where -70 ml of suspension was consumed for each dose and availability of prevaccination and 21-day postvaccination blood samples of adequate volume. Adjusting for the inclusion criteria and the individual dropped because of antibiotic treatment (see above) resulted in groups of 13 Ingestion of Ty2la diluted in milk is established as a safe and immunogenic vaccination regimen for school-age children and adults (6, 21) , and Chilean school-age children (6 to 9 years old) show 42% seroconversion after ingestion of Ty2la diluted in bicarbonate-containing milk (4) . Thus, the finding that the vaccine was well tolerated was expected. However, it was surprising that this formulation failed to cause an anti-S. typhi immune response in infants and toddlers.
Because of the result presented above, two subsequent studies were made in which Ty2la was delivered to children 2 to 3.5 years of age (10) . In the first study (with 24 vaccine recipients and 25 placebo recipients), a humoral immune response to S. typhi was found for 8 (33%) vaccine recipients (5 responders to 0 antigen [IgG], 3 responders to H antigen).
In the second study (with 17 vaccine recipients and 24 placebo recipients), no humoral immune response followed vaccination. In these studies, diarrhea, fever, vomiting, or abdominal pain was observed on average in 4% of the recipients of the vaccine or placebo and no skin reactions were observed.
The composite result demonstrates that the Ty2la vaccine obtained from lots used successfully to immunize school-age children and adults (3, 4, 11) was markedly less immunogenic for children <5 years old. Because cultures established that sufficient viable bacteria were present in the milk and controls showed immunoassays to be functioning appropri- (6) Adult controls
History of typhoid (1) 40 ( are not reported for paired samples of IgA anti-O because the level of rise in net optical density corresponding to significant response has not been determined. As determined by using the paired t test, none of the serological assays differed significantly between day 0 and day 21 specimens in either controls or vaccinees (P -0.28 and P 2 0.18, respectively). For lymphocyte replicative responses, the day 21 response to phytohemagglutinin (PHA) among controls was significantly greater than that on day 0 (P = 0.007); all other comparisons were not significant for controls (P 2 0.11) and vaccinees (P 2 0.19). PWM, pokeweed mitogen. 
